Results 51 to 60 of about 264,257 (370)

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

New England Journal of Medicine, 2019
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, Joy P. Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz   +23 more
semanticscholar   +1 more source

Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas

Haematologica, 2008
Background Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned.Design and Methods We studied the gene expression profile of 43 follicular lymphomas, 50 B-cell non-Hodgkin’s lymphomas of
Pier Paolo Piccaluga, Andrea Califano, Ulf Klein, Claudio Agostinelli, Beatriz Bellosillo, Eva Gimeno, Sergi Serrano, Francisco Solè, Yonghui Zang, Brunangelo Falini, Pier Luigi Zinzani, Stefano A. Pileri   +11 more
doaj   +1 more source

Concurrent myasthenia gravis-related cervical thymoma in a patient with diffuse large B-cell lymphoma: a case report

Journal of Medical Case Reports, 2022
Background Cervical thymoma is a rare thymic epithelial neoplasm. Evidence supports an increased risk of second primary malignancies in patients with thymoma.
Chutima Kunacheewa, Sattawut Wongwiangjunt, Sanya Sukpanichnant   +2 more
doaj   +1 more source

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

New England Journal of Medicine, 2002
BACKGROUND The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival.
A. Rosenwald, George W. Wright, W. Chan, J. Connors, E. Campo, R. Fisher, R. Gascoyne, H. Muller-Hermelink, E. Smeland, J. Giltnane, E. Hurt, Hong Zhao, Lauren Averett, Liming Yang, W. Wilson, E. Jaffe, R. Simon, R. Klausner, J. Powell, P. Duffey, D. Longo, T. Greiner, D. Weisenburger, W. Sanger, B. Dave, J. Lynch, J. Vose, J. Armitage, E. Montserrat, A. López-Guillermo, T. Grogan, T. Miller, M. LeBlanc, G. Ott, S. Kvaløy, J. Delabie, H. Holte, P. Krajči, T. Stokke, L. Staudt   +39 more
semanticscholar   +1 more source

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Nature Medicine, 2022
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL).
E. Bachy, S. le Gouill, Roberta Di Blasi, P. Sesques, G. Manson, G. Cartron, D. Beauvais, L. Roulin, F. Gros, M. Rubio, P. Bories, J. Bay, C. C. Llorente, S. Choquet, R. Casasnovas, M. Mohty, S. Guidez, M. Joris, M. Loschi, S. Carras, J. Abraham, A. Chauchet, Laurianne Drieu La Rochelle, B. Deau-Fischer, O. Hermine, T. Gastinne, J. Tudesq, E. Gat, F. Broussais, C. Thieblemont, R. Houot, F. Morschhauser   +31 more
semanticscholar   +1 more source

Diffuse Large B-Cell Lymphoma of the Prostate [PDF]

Archives of Pathology & Laboratory Medicine, 2014
In this article, we review prostatic lymphomas and discuss the differential diagnosis of high-grade malignant neoplasms of the prostate. We illustrate this with a case of a 46-year-old man seen with lower urinary tract obstruction who had diffuse involvement by a high-grade malignancy on prostate biopsy.
Joshua I, Warrick, Scott R, Owens, Scott A, Tomlins   +2 more
openaire   +2 more sources

Transplant in Diffuse Large B-Cell Lymphoma

Brazilian Journal of Transplantation, 2022
Diffuse large B-cell lymphoma is the most common type of aggressive lymphoma. Patients that don’t respond to first-line therapy have a poor prognosis.
Guilherme Duffles, Carmino De Souza
doaj   +3 more sources

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma

Haematologica, 2011
Background Mediastinal gray zone lymphoma is a newly recognized entity with transitional morphological and immunophenotypic features between the nodular sclerosis subtype of Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma.
Franziska C. Eberle, Jaime Rodriguez-Canales, Lai Wei, Jeffrey C. Hanson, J. Keith Killian, Hong-Wei Sun, Lisa G. Adams, Stephen M. Hewitt, Wyndham H. Wilson, Stefania Pittaluga, Paul S. Meltzer, Louis M. Staudt, Michael R. Emmert-Buck, Elaine S. Jaffe   +13 more
doaj   +1 more source

The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells

Haematologica, 2017
The forkhead transcription factor FOXP1 is generally regarded as an oncogene in activated B cell-like diffuse large B-cell lymphoma. Previous studies have suggested that a small isoform of FOXP1 rather than full-length FOXP1, may possess this oncogenic ...
Martine van Keimpema, Leonie J. Grüneberg, Esther J.M. Schilder-Tol, Monique E.C.M. Oud, Esther A. Beuling, Paul J. Hensbergen, Johann de Jong, Steven T. Pals, Marcel Spaargaren   +8 more
doaj   +1 more source

Diffuse large B-cell lymphoma with uncommon cardiac invasion

SAGE Open Medical Case Reports, 2022
Diffuse large B-cell lymphoma is the most common histologic subtype of non-Hodgkin lymphoma. Secondary involvement of the heart is seen late in advanced cases, it is uncommon for diffuse large B-cell lymphoma to present as intracardiac mass.
Yunis Daralammouri, Hamza Hamayel, Yahya Ismail, Sajed Majadla, Razan Odeh   +4 more
doaj   +1 more source